In addition, compared to benign breast tumours, the methylation levels of IL21R were significantly lower in BC patients with triple-negative, covariates adjusted ORs were more than 1.54 for per 10% reduction in methylation level of each CpG site (Figure 3d, Table S8). The gene discussed is IL21R; the disease is breast cancer.